The AA2-Ratio: A Novel Diagnostic Biomarker for Primary Aldosteronism

Projektinformationen

PANOSTICS

ID Finanzhilfevereinbarung: 673072

DOI 10.3030/673072

Abgeschlossenes Projekt

EK-Unterschriftsdatum 22 April 2015

Startdatum 1 April 2015

Enddatum 31 August 2015

Finanziert unter

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Gesamtkosten € 71 429,00

EU-Beitrag € 50 000,00

Koordiniert durch

ATTOQUANT DIAGNOSTICS GMBH
Austria

Ziel

“PANOSTICS” comprises the validation and clinical implementation of a versatile and cost effective diagnostic blood test for the detection of primary aldosteronism (PA) among hypertensive patients. The Aldosterone-to-Angiotensin II-Ratio (AA2-Ratio) is a mass spectrometry based diagnostic biomarker for PA. We are planning to sell this diagnostic blood test to clinical institutions in a fee-for-service business model. Our vision is to build up a European network of qualified fee-for-service laboratories focused on hypertension-associated biomarkers. The market entry for the AA2-Ratio is planned via a subsidiary laboratory in Germany. Full commercialization of the AA2-Ratio shall be achieved by implementation into standard clinical practice for the classification and treatment of resistant hypertension.
Hypertension has been clearly shown to be the most important cause of morbidity and mortality worldwide, representing a severe challenge for future healthcare systems. Up to 11,9 million people in Europe are referred to be resistant hypertensive, meaning that they cannot be cured by standard treatments. PA is a certain form of resistant hypertension that can be easily cured by appropriate second-line drug treatments or surgical procedures, if detected. Recommendations by clinical societies suggest extensive screening efforts to facilitate an early detection of PA among resistant hypertensive patients. However, actual clinical practice in Europe does not follow these guidelines due to the lack of appropriate and cost effective screening procedures. If PA remains undiagnosed, it caused severe hypertension frequently resulting in cardiovascular complications including heart attacks and strokes.
The AA2-Ratio is a diagnostic biomarker for PA, that is superior to state-of-the-art assays and allows for a highly specific and cost effective diagnosis of PA among hypertensive patients.

Wissenschaftliches Gebiet

• medical and health sciences › clinical medicine › surgery › surgical procedures
• medical and health sciences › clinical medicine › cardiology › cardiovascular diseases
• medical and health sciences › basic medicine › neurology › stroke
• natural sciences › chemical sciences › analytical chemistry › mass spectrometry
• engineering and technology › medical engineering › medical laboratory technology › laboratory samples analysis

Programm/Programme

• H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme
• H2020-EU.3.1.3. - Treating and managing disease

Thema/Themen

• PHC-12-2014-1 - Clinical research for the validation of biomarkers and/or diagnostic medical devices

Aufforderung zur Vorschlagseinreichung

H2020-SMEInst-2014-2015

Andere Projekte für diesen Aufruf anzeigen

Unterauftrag

H2020-SMEINST-1-2014

Finanzierungsplan

SME-1 - SME instrument phase 1

Koordinator

ATTOQUANT DIAGNOSTICS GMBH

• Netto-EU-Beitrag: € 50 000,00
• Adresse: CAMPUS VIENNA BIOCENTER 5 ; 1030 WIEN ; Österreich
• KMU Die Organisation definierte sich zum Zeitpunkt der Unterzeichnung der Finanzhilfevereinbarung selbst als KMU (Kleine und mittlere Unternehmen). Ja:
  Region
  Ostösterreich › Wien › Wien
• Region: Ostösterreich › Wien › Wien
• Aktivitätstyp: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Gesamtkosten: € 71 429,00